Tradestie Institutional Equity Comparison Engine
EVMN vs JBIO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
EVMN Overall Edge
EVMN Captures Institutional Edge (2โ1 Pillars ยท 1โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Evommune, Inc. (EVMN) driven by superior Growth & Margin, Options & Structure while JBIO counters with relative strength in Momentum & Technical. Fundamentally, EVMN trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus JBIO at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, EVMN sits in SURGE (53rd %ile IV; Dealer Gamma Walls on Pro) against JBIO sits in BREAKDOWN (100th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
EVMN N/M vs JBIO N/M Fwd P/E
Growth & Margin Winner
EVMN
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner
JBIO
1Y -61.0% vs +58.4% ยท 52W Pos 8% vs 32%
Options & Structure Winner
EVMN
SURGE (53rd %ile IV) vs BREAKDOWN (100th %ile IV)
EVMN
US Equity
Evommune, Inc.
Pharmaceutical Preparations
$7.10
-6.95% 1D
Market Cap
$315.5M
1M Return
+37.33%
1Y Return
-61.03%
Forward P/E
N/M
Unified AI Score
30.0 / 100
SELL
Tech 50.0
Fund 35.0
Flow 69.0
Mom 44.0
JBIO
NASDAQ
Jade Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$15.34
-4.99% 1D
Market Cap
$1.0B
1M Return
+13.85%
1Y Return
+58.42%
Forward P/E
N/M
Unified AI Score
32.6 / 100
SELL
Tech 20.0
Fund 44.0
Flow 73.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
EVMN -61.03%
JBIO +58.42%
Spread: +119.45 pp (JBIO Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
EVMN TTM Op. Margin: 0.0%
JBIO TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EVMN vs JBIO. Trailing 12-month operating profitability (EVMN 0.0% vs JBIO 0.0%) and valuation multiples (EVMN N/M vs JBIO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | EVMN | JBIO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $315.5M | $1.0B | Larger Scale | JBIO |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | +0.0% | Higher Growth | Tie |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -69.5% | -89.2% | Higher ROE | EVMN |
| 52-Week Range Position Momentum | 8% ($5โ$33) | 32% ($10โ$28) | Stronger Trend | JBIO |
| Beta / 30D Volatility Risk Regime | 1.05ฮฒ ยท 118% Vol | 1.32ฮฒ ยท 57% Vol | Lower Realized Risk | JBIO |
| Unified Institutional Score Composite Signal | 30.0 / 100 (SELL) | 32.6 / 100 (SELL) | Higher Composite | JBIO |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full EVMN vs JBIO Buy Guide
EVMN
SURGE
5d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
53rd %ile
IV Regime
Balanced (25thโ60th %ile)
JBIO
BREAKDOWN
141d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
100th %ile
IV Regime
Extreme (>80th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither EVMN nor JBIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.